drugset / Trial / NCT03029988
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Phase 1
Terminated
3 enrolled
Navidea Biopharmaceuticals
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedSequentialOpen-labelDiagnostic
Summary
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
Timeline
- Start
- 2017-07-26
- Primary completion
- 2018-09-24
- Completion
- 2018-09-24
Outcome
Outcome not reported
Stopped: “Lack of effect in Cohort 1”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tilmanocept | Diagnostic / imaging agent | 50 ug | Intravenous |
| Subject | Tilmanocept | Diagnostic / imaging agent | 200 ug | Intravenous |